Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LSS | P48449 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.46 |
| ▸ | GCGR | P47871 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GIPR | P48546 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13800496 | 0.83 | MAPT (0.47) | MCHR1LSSTMEM97SIGMAR1SMN1; SMN2 | |
| SCHEMBL2663436 | 0.82 | SIGMAR1 (0.55) | CA1CA2MAPK1TMEM97SIGMAR1 | |
| SCHEMBL13800570 | 0.81 | CA1 (0.50) | MCHR1CA1CA2MAPK1TMEM97 | |
| SCHEMBL13800502 | 0.79 | CA1 (0.45) | MCHR1CA1CA2MAPK1TMEM97 | |
| SCHEMBL9717434 | 0.78 | MAPK1 (0.71) | CA1CA2MAPK1HRH3SMN1; SMN2 | |
| SCHEMBL2663435 | 0.78 | CA1 (0.52) | CA1CA2MAPK1TMEM97SIGMAR1 | |
| SCHEMBL3199550 | 0.77 | GCGR (0.58) | CA1CA2MAPK1GCGRHRH3 | |
| SCHEMBL13799721 | 0.77 | ALDH1A1 (0.52) | HRH3SMN1; SMN2L3MBTL1 | |
| SCHEMBL14045108 | 0.76 | MCHR1 (0.62) | MCHR1LSSTMEM97SIGMAR1SMN1; SMN2 | |
| SCHEMBL2650667 | 0.75 | LSS (0.58) | MCHR1CA1CA2LSSTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | MCHR1 178/4885CA1 4464/4885CA2 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.